Kcentra

DRUG3 trials

Sponsors

Thomas Jefferson University, University of Maryland, Baltimore, Octapharma

Conditions

Heart Disease End StageHeart Failure，CongestiveSignificant Bleeding RiskThrombosisVitamin K-Dependent Coagulation Defect

Phase 1

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

CompletedNCT02270918

Thomas Jefferson UniversityThrombosis

Start: 2014-11-30End: 2014-12-31Updated: 2016-06-07

Phase 3

Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation

TerminatedNCT03341156

University of Maryland, BaltimoreHeart Disease End Stage, Heart Failure，Congestive

Start: 2018-07-11End: 2025-02-20Updated: 2025-05-23

Unknown Phase

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Active, not recruitingNCT06429787

OctapharmaSignificant Bleeding Risk, Vitamin K-Dependent Coagulation Defect

Start: 2025-02-14End: 2032-06-30Target: 3574Updated: 2026-09-15

Related Papers

Prothrombin complex concentrate in managing direct oral anticoagulant (DOAC)-associated bleeding and real-world use in vitamin k antagonist (VKA)-associated bleeding: The ongoing lex-210 and lex-212 studies

Blood2025-11-03